The Haavind Pharma Report Winter 2019
In the Pharma Report Winter 2019, we take a retrospective view on some of the legal developments during the second half of 2018 in the Norwegian pharmaceutical sector.
The innovation-driven and complex healthcare and life science sector is heavily regulated and companies must often operate in a crossing point between different intersecting sets of rules.
Our lawyers have the necessary insight and legal expertise to offer our customers sound and commercially oriented advice. We handle complex and comprehensive processes as well as minor assignments related to IPR, competition law, regulatory issues, contract law, financing and corporate law, for large global enterprises as well as entrepreneurs and growth companies.
As the only Norwegian member of the European law network Conferénce Bleue we have unique access to legal expertise on pharmaceutical, healthcare and medical equipment law, in most European countries.